for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott Laboratories

ABT.N

Latest Trade

106.66USD

Change

0.96(+0.91%)

Volume

1,629,701

Today's Range

104.51

 - 

106.75

52 Week Range

61.62

 - 

114.19

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
105.70
Open
104.80
Volume
1,629,701
3M AVG Volume
111.90
Today's High
106.75
Today's Low
104.51
52 Week High
114.19
52 Week Low
61.62
Shares Out (MIL)
1,770.53
Market Cap (MIL)
187,145.00
Forward P/E
32.88
Dividend (Yield %)
1.36

Next Event

Q3 2020 Abbott Laboratories Earnings Release

Latest Developments

More

Abbott Laboratories- Freestyle Libre 2 Now Available To Medicare Patients

Abbott Receives FDA Approval For Ios-Compatible App Allowing People Living With Chronic Pain And Movement Disorders To Personalize Therapy Via Their Mobile Device

Abbott CEO Says "It's Clear That The Need For Testing Is Large And It Isn't Going Away" - Conf Call

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry

Medical Equipment & Supplies

Contact Info

100 Abbott Park Rd

ABBOTT PARK, IL

60064-3500

United States

+1.224.6676100

https://www.abbott.com

Executive Leadership

Miles D. White

Executive Chairman of the Board

Robert B. Ford

President, Chief Executive Officer, Chief Operating Officer, Director

Robert E. Funck

Chief Financial Officer, Executive Vice President - Finance

Hubert L. Allen

Executive Vice President, General Counsel, Secretary

Mary K. Moreland

Executive Vice President of Human Resources

Key Stats

1.90 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

27.4K

2018

30.6K

2019

31.9K

2020(E)

33.1K
EPS (USD)

2017

2.500

2018

2.880

2019

3.240

2020(E)

3.295
Price To Earnings (TTM)
61.14
Price To Sales (TTM)
5.95
Price To Book (MRQ)
6.12
Price To Cash Flow (TTM)
29.97
Total Debt To Equity (MRQ)
64.36
LT Debt To Equity (MRQ)
59.47
Return on Investment (TTM)
5.28
Return on Equity (TTM)
4.49

Latest News

Latest News

In-house counsel on the move: Broadmark REIT taps new GC as pandemic roils industry

Broadmark Realty Capital Inc, a real estate investment trust (REIT), has appointed former Ventas Inc attorney Nevin Boparai as its chief legal officer as the coronavirus pandemic shakes up the market for commercial space.

Fed Circuit: PTAB judges can review patents Iancu litigated while at Irell

U.S. Patent and Trademark Office administrative judges can review a patent that the office's director Andrei Iancu litigated while in private practice, a federal appeals court said on Wednesday, rejecting an argument that their loyalty to him might cloud their judgment.

U.S. to send millions of rapid COVID-19 tests to states to support school reopening, other tasks

The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories <ABT.N> last week to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a...

UPDATE 1-U.S. to send millions of rapid COVID-19 tests to states to support school reopening, other tasks

The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories last week to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a press briefing...

U.S. to send millions of rapid COVID-19 tests to states to support school reopening, other tasks

The U.S. government will send an "overwhelming majority" of the rapid COVID-19 tests it purchased from Abbott Laboratories last week to governors of U.S. states and territories to support school reopening and other critical tasks, an administration official said at a press...

Breakingviews - Corona Capital: Abbott’s test, Dollar General

Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

Trump administration to purchase 150 million Abbott COVID-19 tests for $750 million

The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories <ABT.N> for about $750 million, a White House spokeswoman said on Thursday.

Trump administration to purchase 150 million Abbott COVID-19 tests for $750 mln

The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories for about $750 million, a White House spokeswoman said on Thursday.

Abbott wins U.S. authorization for $5 rapid COVID-19 antigen test

Abbott Laboratories <ABT.N> said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5.

Abbott wins U.S. approval for rapid COVID-19 test

Abbott Laboratories said on Wednesday it won U.S. marketing approval for a COVID-19 portable test that can deliver results within 15 minutes.

Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

Abbott Laboratories <ABT.N> expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.

Abbott sees no hit to demand for COVID-19 tests from vaccine

Abbott Laboratories <ABT.N> said on Thursday demand for its coronavirus tests will likely remain high even after a safe and effective vaccine is available as the medical device maker forecast full-year profit above analysts' estimates.

BRIEF-Abbott CEO Says "It's Clear That The Need For Testing Is Large And It Isn't Going Away" - Conf Call

* ABBOTT CEO SAYS AT THE END OF JUNE, PROCEDURE VOLUMES REBOUNDED TO 90% OF PRE-CRISIS LEVELS ON AVERAGE IN U.S. - CONF CALL

REFILE-Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.

Abbott quarterly profit plunges as COVID-19 batters medical device unit

Abbott Laboratories on Thursday reported a 46.6% fall in second-quarter profit as the COVID-19 pandemic continued to batter its medical device unit.

BRIEF-Abbott Receives FDA Approval For Heart Rhythm Devices With Bluetooth Connectivity, Continuous Remote Monitoring

* ABBOTT RECEIVES FDA APPROVAL FOR NEW HEART RHYTHM DEVICES FEATURING BLUETOOTH CONNECTIVITY AND CONTINUOUS REMOTE MONITORING Source text for Eikon: Further company coverage:

BRIEF-Abbott, Tandem Diabetes Care Advance Development of Technologies for Insulin Delivery Systems

* ABBOTT - COS PARTNER TO INTEGRATE ABBOTT'S FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITORING TECHNOLOGY WITH TANDEM'S INSULIN DELIVERY PRODUCTS Source text for Eikon: Further company coverage:

BRIEF-Abbott Laboratories Files For Potential 2-Part, Notes Offering

* ABBOTT LABORATORIES FILES FOR POTENTIAL 2-PART, NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/3hT6Zrw) Further company coverage:

BRIEF-Abbott Laboratories Files For Potential Debt Shelf Offering

* ABBOTT LABORATORIES SAYS IT FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source: (https://bit.ly/3i0wEim) Further company coverage:

U.S. FDA clears new version of Abbott's low-cost glucose monitor

The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' continuous glucose monitoring device, helping the company build upon the success of its fastest-growing diabetes product.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up